Recombinant Human Interferon Lambda-1 Protein (IFNL1), Active

Name: Recombinant Human Interferon Lambda-1 Protein (IFNL1), Active
Brand: Beta LifeScience
SKU: BLC-06064P
Price: 287.2 USD
Availability: InStock

Collections: Cytokines, Cytokines and growth factors, Interferons and receptors (ifn), Interleukins and receptors, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Interferon Lambda-1 Protein (IFNL1), Active is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 97% as determined by SDS-PAGE and HPLC.
Endotoxin	Less than 1.0 EU/μg as determined by LAL method.
Activity	Fully biologically active when compared to standard. The ED50 as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5 ng/ml, corresponding to a specific activity of >2.0x10 5 IU/mg.
Uniprotkb	Q8IU54
Target Symbol	IFNL1
Synonyms	IFN-lambda-1, Interleukin-29, IL-29
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	Tag-Free
Complete Sequence	GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES T
Expression Range	20-200aa
Protein Length	Full Length of Mature Protein
Mol. Weight	19.8 kDa
Research Area	Immunology
Form	Lyophilized powder
Buffer	Lyophilized from a 0.2 μm filtered PBS, pH 7.4
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Cytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression.
Subcellular Location	Secreted.
Protein Families	Lambda interferon family
Database References	HGNC: 18363 OMIM: 607403 KEGG: hsa:282618 STRING: 9606.ENSP00000329991 UniGene: Hs.406745

Gene Functions References

SOCS2 impairs IFN/JAK/STAT signaling through reducing the stability of tyrosine kinase 2 (TYK2), downregulating the expression of type I and III IFN receptors, attenuating the phosphorylation and nucleus translocation of STAT1. PMID: 28496097
In conclusion, IL-29 enhanced CXCL10 production in human oral epithelial cells via the p38 MAPK, STAT3, and NF-kappaB pathways, which might control Th1-cell accumulation in periodontal lesions and be involved in pathological processes in periodontal disease. PMID: 28753407
The DNA binding domain of Ku70 was essential for formation of the Ku70-STING complex. Knocking down STING in primary human macrophages inhibited their ability to produce IFN-lambda1 in response to transfection with DNA or infection with the DNA virus HSV-2 (herpes simplex virus-2). Together, these data suggest that STING mediates the Ku70-mediated IFN-lambda1 innate immune response to exogenous DNA or DNA virus infection. PMID: 28720717
The review focuses on the value of the type I and III interferon subtypes (alphas, beta and lambdas) as therapeutics for prevention and treatment of viral infections (influenza, herpes, human immunodeficiency virus and hepatitis viruses). PMID: 27544015
Interferon lambda1/IL-29 and inorganic polyphosphate are novel regulators of neutrophil-driven thromboinflammation. PMID: 28678391
IFN-lambda1 may play an important role in anti-respiratory syncytial virus infection. PMID: 28606236
Ebola virus VP24, in addition of inhibiting IFN-induced antiviral responses, was found to efficiently inhibit type III IFN-lambda1 gene expression. PMID: 28595092
STAT2 recruits USP18 to the type I IFN receptor subunit IFNAR2 via its constitutive membrane-distal STAT2-binding site. PMID: 28165510
IFN-lambda1 is likely to play a role in the pathogenesis of CSU. Blocking IFN-lambda1 production may help to reduce the accumulation of inflammatory cells in the involved CSU skin. PMID: 27445435
IL-29 stimulates inflammation and cartilage degradation by OA FLS, indicating that this cytokine is likely involved in the pathogenesis of OA. PMID: 27433031
IL-29 is a potential biomarker for disease activity in anti-cyclic citrullinated peptide-antibodies positive rheumatoid arthritis patients. PMID: 28154345
this study shows that serum levels of IL-29 play a role in the pathogenesis of Hashimoto's thyroiditis in Turkey PMID: 27617784
serum levels of IL-32 and TNF-alpha may be diagnostic markers, and serum IL-29 levels may be associated with good prognosis in patients with gastric cancer PMID: 26219901
Serum levels of IL-29 and IFN-gamma are predictive of relapse outcomes after hepatitis C treatment. PMID: 26342113
IL-29 selectively induces CXCR3A-binding chemokines (CXCL9, CXCL10, CXCL11) in skin cells. Murine IL-29 counterpart induces skin T-cell infiltration and inflammation in mice. PMID: 26612594
activation of TLR7 upregulated the expression levels of IFN-lambda1 and MMP-9 were increased by ~3 fold, whereas other genes (p53, PTEN, TIMP-1) were upregulated by ~2 fold, and VEGF was marginally upregulated after 10 min. PMID: 26718740
IL-29 directly induces RANKL expression in rheumatoid arthritis-fibroblasts like synoviocytes via MAPK signaling pathway. PMID: 26420479
showed that silencing IFN-lambda1 in T/T cell line reduced basal IFN-stimulated gene expression and improved antiviral activity PMID: 26896692
IFN-lambda-1 and interferon-gamma levels in systemic sclerosis patients were significantly higher than those in healthy individuals. PMID: 26057401
this study failed to prove any significant association between polymorphisms in IL29 gene rs30461 or IL10 gene (-1082, -819 and -592) or cytokine haplotype and either response to therapy or severity of HCV infection in children. PMID: 25936570
IL-29 can aggravate LPS/TLR4-mediated inflammation. PMID: 26278073
NS of severe fever with thrombocytopenia syndrome virus inhibited the activity of IFN-alpha1, IFN-beta, IFN-lambda1 and IFN-lambda2 through inhibition of STAT1 phosphorylation. PMID: 26353965
the role of IFN-lambda in IDO regulation was investigated after influenza infection of respiratory epithelial cells. PMID: 25756191
Data suggest that naturally occurring iDVGs (immunostimulatory defective viral genomes) trigger robust host antiviral/innate immunity responses including/requiring up-regulation of IFNL1 and IFNB1 (interferon beta 1) in respiratory mucosa. PMID: 26336095
there seems to be an inverse link between IFN-lambda and the severity of allergic asthma and allergic asthma exacerbations. PMID: 25592858
Studies indicate that the type III interferons (IFNs) or IFN-lambdas consists of four members: IFN-lambda1 (IL-29), IFN-lambda2 (IL28A), IFN-lambda3 (IL-28B) and IFN-lambda4. PMID: 26194286
Increased quantity of IL-29 in GCF and plasma of subjects with periodontitis suggests a role in pathogenesis of periodontitis and the SNP (rs30461) is not related to susceptibility to periodontitis in this population of Indian individuals. PMID: 25255471
Severity of rhinovirus-induced asthma symptoms is inversely related to resolution IFNL1 expression. PMID: 25784275
IL-29 is dysregulated in patients with rheumatoid arthritis (RA), which may contribute to the RA pathogenesis via inducing the production of proinflammatory cytokines, chemokines or matrix metalloproteinases in synovial fibroblasts. PMID: 23078630
intranasal delivery of adenovirus expressing protein suppresses allergic asthma in a murine model PMID: 24819718
IFN-lambda1-mediated IL-12 production in macrophages induces IFN-gamma production in human NK cells. PMID: 25316442
data suggest that the p38alpha MAPK pathway is linked with RLR signaling pathways and regulates the expression of early IFN genes after RNA stimulation cooperatively with IRF3 and NF-kappaB to induce antiviral responses further PMID: 25473098
Interferon lambda 1 induces antiviral response to herpes simplex virus 1 infection. PMID: 25518713
These results show that type III interferons (IFN-lambdas) play a critical protective role in human metapneumovirus infection. PMID: 25355870
Results showed no association between genotypes and alleles of IL28A, IL28B or IL29 polymorphisms and Hepatitis C virus infection. PMID: 24269996
This study is the first to show the activation of a type III interferon response in low-risk human papillomavirus positive cervical cells and suggests that the lack of this response may be related to lesion progression. PMID: 24510368
our data suggest that human but not mouse hepatocytes are responsive to IFN-lambda in vivo. PMID: 24498220
protein expression is inhibited by hepatitis C virus PMID: 23529855
IFNL1 expression in the human colon is transcriptionally regulated by ZEB-1, BLIMP-1, and NF-kappaB p50 and p65. PMID: 24140069
These data suggest that T(Helper)17 cell-derived IL-29, which is absent in atopic dermatitis, mediates the robust antiviral state on psoriatic skin, and demonstrate a new function of T(H)17 cells. PMID: 24068736
HBV infection upregulates IL-27 expression, which, in turn, stimulates IFN-lambda1 production. PMID: 24337382
Interferon regulatory factor (IRF)-3 and -7 are the key transcriptional factors for the induction of IL-28A and IL-28B genes, whereas NF-kappaB is an additional requirement for the induction of the IL-29 gene. PMID: 24385435
IL-32 levels during viral infection mediate antiviral effects by stimulating the expression of IFN-lambda1. PMID: 23729669
IFN-lambdas can also directly affect T cells through inhibition of the T helper 2 cell (Th2) responses. IFN-lambdas have varying immunomodulatory functions under different physiological conditions PMID: 23207147
RA patients that presented knee joint involvement displayed higher serum IFN-lambda1 than patients without knee joint involvement, suggesting that abnormally elevated IFN-lambda1 levels in RA can associate with knee joint disease. PMID: 23039206
The viral infection induced both IFN-lambda1 promoter activity and that of the 3'-untranslated region (UTR), indicating that IFN-lambda1 expression is also regulated at the post-transcriptional level. PMID: 23150165
IL-29 can regulate expression of protease activated receptors and tryptase- and trypsin-induced IL-4 production in mast cells. PMID: 23218741
These data support a model of coordinated cell- and ligand-specific expression of types I and III interferon. PMID: 22249201
After non-surgical periodontal therapy, IL-29 levels increased both in chronic and aggressive periodontitis patients. PMID: 23151616
IFN-alpha and IFN-lambda signal through distinct receptors, they induce expression of a common set of ISGs in hepatocytes. However, unlike IFN-alpha, IFN-lambda1 did not induce STAT activation or ISG expression by purified lymphocytes or monocytes PMID: 23258595

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.